As it rages, the semaglutide debate exposes public trust deficit in healthcare

The contentious debate around semaglutide in South African healthcare extends beyond its use for obesity and type 2 diabetes, exposing deep-seated issues of access, affordability, regulation, and the pharmaceutical industry's role. At its core, the discussion highlights a significant deficit in public trust in the institutions responsible for health.